Table 1 Association between heparanase (by IHC) expression and pathological clinical parameters in ER+ breast cancer.
From: Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
Heparanase | |||||||
|---|---|---|---|---|---|---|---|
All (N = 641) | Negative (N = 611) | Positive (N = 30) | p-value | ||||
Age, years | |||||||
<50 | 339 | 53% | 322 | 53% | 17 | 57% | 0.67 |
≥50 | 302 | 47% | 289 | 47% | 13 | 43% | |
No. of involved nodes | |||||||
1–3 | 345 | 54% | 327 | 54% | 18 | 60% | 0.47 |
4–10 | 212 | 33% | 205 | 34% | 7 | 23% | |
>10 | 84 | 13% | 79 | 13% | 5 | 17% | |
Tumor size, no. | |||||||
≤2 cm | 207 | 33% | 197 | 33% | 10 | 33% | 0.93 |
>2 cm | 429 | 67% | 409 | 67% | 20 | 67% | |
pTx | 5 | 5 | |||||
Tumor grade, no. | |||||||
G1-G2 | 340 | 55% | 322 | 55% | 18 | 60% | 0.59 |
G3 | 276 | 45% | 264 | 45% | 12 | 40% | |
Gx | 25 | 25 | |||||
ER, no. | |||||||
ER− | 51 | 8% | 49 | 8% | 2 | 7% | 1 |
ER+ | 585 | 92% | 558 | 92% | 27 | 93% | |
Missing info | 5 | 4 | 1 | ||||
PR, no. | |||||||
PR− | 101 | 16% | 97 | 16% | 4 | 14% | 1 |
PR+ | 526 | 84% | 501 | 84% | 25 | 86% | |
Missing info | 14 | 13 | 1 | ||||
HER2, no. | |||||||
HER2− | 526 | 83% | 505 | 84% | 21 | 70% | 0.07 |
HER2+ | 105 | 17% | 96 | 16% | 9 | 30% | |
Missing info | 10 | 10 | |||||
KI-67, no. | |||||||
<14 | 139 | 22% | 138 | 23% | 1 | 3% | 0.006 |
≥14 | 480 | 78% | 451 | 77% | 29 | 97% | |
Missing info | 22 | 22 | |||||
